1例药源性重度血小板减少症的病例分析  被引量:1

Medication analysis of one patient with severe drug-induced thrombocytopenia

在线阅读下载全文

作  者:周庆秋[1] 吴云 ZHOU Qing-qiu1, WU Yun2(1. Dept. of Pharmacy, Taian Central Hospital, Taian 271000, China; 2. Heart Centre,Taian Central Hospital, Taian 271000,China)

机构地区:[1]泰山医学院附属泰山医院药学部,山东泰安271000 [2]泰山医学院附属泰山医院心脏中心,山东泰安271000

出  处:《泰山医学院学报》2018年第7期776-778,共3页Journal of Taishan Medical College

摘  要:目的探讨急性心肌梗死患者经皮冠脉介入治疗术后发生严重药源性血小板减少症(DITP)的相关药物。方法临床药师对该例患者的用药情况进行分析,协助制定药源性血小板减少症的对症治疗方案并全程实施药学监护。结果临床药师判定替罗非班为致血小板减少症的可疑药物。经对症治疗后,患者血小板逐渐恢复正常,病情缓解出院。结论临床药师参与药源性血小板减少症患者的治疗与监护,可减少不良反应的发生,保障患者的用药安全。Objective: To investigate the related drugs of severe drug-induced thrombocytopenia in patients with acute myocardial infarction after percutaneous coronary intervention(PCI). Methods: The typical cases whose treatment was participated by clinical pharmacist were analyzed from three aspects of analyzation of drugs that caused drug-induced thrombocytopenia,formulation of therapeutic regimen and implementation of pharmaceutical care. Results: Tirofiban as a suspect drug for thrombocytopenia was identified. Platelets of the patient gradually returned to normal level with symptomatic treatment. The patient discharged after symptomatic remission. Conclusion: Clinical pharmacists participated in the treatment and monitoring of patients with drug-induced thrombocytopenia,can reduce the occurrence of adverse reactions and ensure the safety of patients.

关 键 词:药源性血小板减少症 临床药师 肝素 替罗非班 药学监护 

分 类 号:R969[医药卫生—药理学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象